109 related articles for article (PubMed ID: 16526183)
1. [Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].
Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1173-84. PubMed ID: 16526183
[TBL] [Abstract][Full Text] [Related]
2. [Calcium balance and regulation in schizophrenic patients treated with second generation antipsychotics].
Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1157-71. PubMed ID: 16526182
[TBL] [Abstract][Full Text] [Related]
3. [Osteoporosis risk factors among patients with schizophrenia].
Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
Przegl Lek; 2006; 63(3):134-8. PubMed ID: 16969898
[TBL] [Abstract][Full Text] [Related]
4. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.
Becker D; Liver O; Mester R; Rapoport M; Weizman A; Weiss M
J Clin Psychiatry; 2003 Jul; 64(7):761-6. PubMed ID: 12934975
[TBL] [Abstract][Full Text] [Related]
5. [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].
Wyszogrodzka-Kucharska A; Kunert-Radek J; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1143-55. PubMed ID: 16526181
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis in patients with schizophrenia.
Hummer M; Malik P; Gasser RW; Hofer A; Kemmler G; Moncayo Naveda RC; Rettenbacher MA; Fleischhacker WW
Am J Psychiatry; 2005 Jan; 162(1):162-7. PubMed ID: 15625215
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
O'Keane V; Meaney AM
J Clin Psychopharmacol; 2005 Feb; 25(1):26-31. PubMed ID: 15643097
[TBL] [Abstract][Full Text] [Related]
8. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
Meaney AM; O'Keane V
J Psychopharmacol; 2003 Dec; 17(4):455-8. PubMed ID: 14870961
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in male schizophrenia patients: a review.
Meyer JM; Lehman D
Ann Clin Psychiatry; 2006; 18(1):43-8. PubMed ID: 16517452
[TBL] [Abstract][Full Text] [Related]
10. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.
Doknic M; Maric NP; Britvic D; Pekic S; Damjanovic A; Miljic D; Stojanovic M; Radojicic Z; Jasovic Gasic M; Popovic V
Neuroendocrinology; 2011; 94(3):246-54. PubMed ID: 21986470
[TBL] [Abstract][Full Text] [Related]
11. Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Kinon BJ; Liu-Seifert H; Stauffer VL; Jacob J
Clin Schizophr Relat Psychoses; 2013 Oct; 7(3):115-23. PubMed ID: 23395836
[TBL] [Abstract][Full Text] [Related]
12. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics.
Liu-Seifert H; Kinon BJ; Ahl J; Lamberson S
Ann N Y Acad Sci; 2004 Dec; 1032():297-8. PubMed ID: 15677434
[TBL] [Abstract][Full Text] [Related]
13. Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia.
Petronijevic N; Sopta J; Doknic M; Radonjic N; Petronijevic M; Pekic S; Maric N; Jasovic-Gasic M; Popovic V
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():58-63. PubMed ID: 23811489
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables.
Meaney AM; O'Keane V
Schizophr Res; 2007 Jul; 93(1-3):136-43. PubMed ID: 17467954
[TBL] [Abstract][Full Text] [Related]
15. Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.
Filaković P; Koić O; Laufer D; Radanović-Grgurić L; Degmecić D; Pozgain I
Coll Antropol; 2007 Dec; 31(4):1105-9. PubMed ID: 18217467
[TBL] [Abstract][Full Text] [Related]
16. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.
De Hert M; Detraux J; Stubbs B
Expert Opin Drug Saf; 2016 Jun; 15(6):809-23. PubMed ID: 26986209
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia.
Stubbs B; De Hert M; Sepehry AA; Correll CU; Mitchell AJ; Soundy A; Detraux J; Vancampfort D
Acta Psychiatr Scand; 2014 Dec; 130(6):470-86. PubMed ID: 25041606
[TBL] [Abstract][Full Text] [Related]
18. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
[TBL] [Abstract][Full Text] [Related]
19. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
Bilici M; Cakirbay H; Guler M; Tosun M; Ulgen M; Tan U
Int J Neurosci; 2002 Jul; 112(7):817-28. PubMed ID: 12424822
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
O'Keane V
J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
